Skip to main content
SpringerLink
Log in

Imatinib Mesylate in GIST: profile report

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63(5): 513–22

    Article  PubMed  CAS  Google Scholar 

  2. Judson I. Imatinib mesylate: a viewpoint by Ian Judson. Drugs 2003; 63(5): 523

    Article  Google Scholar 

  3. Van Oosterom A. Imatinib mesylate: a viewpoint by Allan van Oosterom. Drugs 2003; 63(5): 523–4

    Article  Google Scholar 

  4. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61(12): 1765–74; discussion 1775–6

    Article  PubMed  CAS  Google Scholar 

  5. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295(1): 139–45

    PubMed  CAS  Google Scholar 

  6. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 May; 2: 561–6

    Article  PubMed  CAS  Google Scholar 

  7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 Aug 15; 347(7): 472–80

    Article  PubMed  CAS  Google Scholar 

  8. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2002; 38 Suppl. 5: S83–7

    Article  PubMed  Google Scholar 

  9. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001 Oct 27; 358(9291): 1421–3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sarcoma Unit, Royal Marsden Hospital, London, UK

    Ian Judson

  2. Department of Clinical Oncology, Leuven University Hospital, Leuven, Belgium

    Allan van Oosterom

Authors
  1. Ian Judson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allan van Oosterom
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Judson, I., van Oosterom, A. Imatinib Mesylate in GIST: profile report. Drugs Ther. Perspect 19, 4–6 (2003). https://doi.org/10.2165/00042310-200319070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319070-00002

Keywords

Search

Navigation